JP2004500125A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004500125A5 JP2004500125A5 JP2002504285A JP2002504285A JP2004500125A5 JP 2004500125 A5 JP2004500125 A5 JP 2004500125A5 JP 2002504285 A JP2002504285 A JP 2002504285A JP 2002504285 A JP2002504285 A JP 2002504285A JP 2004500125 A5 JP2004500125 A5 JP 2004500125A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- compound
- cells
- gpcrx11
- unknown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 claims description 18
- 108010021336 lanreotide Proteins 0.000 claims description 18
- 229960002437 lanreotide Drugs 0.000 claims description 18
- 102000005962 receptors Human genes 0.000 claims 79
- 108020003175 receptors Proteins 0.000 claims 79
- 210000004027 cell Anatomy 0.000 claims 62
- 150000001875 compounds Chemical class 0.000 claims 60
- 238000000034 method Methods 0.000 claims 47
- 239000002773 nucleotide Substances 0.000 claims 19
- 125000003729 nucleotide group Chemical group 0.000 claims 19
- 102000005157 Somatostatin Human genes 0.000 claims 17
- 108010056088 Somatostatin Proteins 0.000 claims 17
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 17
- 229960000553 somatostatin Drugs 0.000 claims 17
- 230000000694 effects Effects 0.000 claims 16
- 239000000556 agonist Substances 0.000 claims 11
- 229940125425 inverse agonist Drugs 0.000 claims 11
- 238000012216 screening Methods 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 10
- 239000012190 activator Substances 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 239000012528 membrane Substances 0.000 claims 9
- YHIPILPTUVMWQT-UHFFFAOYSA-N Oplophorus luciferin Chemical compound C1=CC(O)=CC=C1CC(C(N1C=C(N2)C=3C=CC(O)=CC=3)=O)=NC1=C2CC1=CC=CC=C1 YHIPILPTUVMWQT-UHFFFAOYSA-N 0.000 claims 8
- 238000005406 washing Methods 0.000 claims 8
- 238000012258 culturing Methods 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 150000001413 amino acids Chemical group 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 5
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 5
- 231100000673 dose–response relationship Toxicity 0.000 claims 5
- 230000003834 intracellular effect Effects 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 238000003745 diagnosis Methods 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 230000000638 stimulation Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 230000004064 dysfunction Effects 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 230000008569 process Effects 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 238000004166 bioassay Methods 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 238000004020 luminiscence type Methods 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000013641 positive control Substances 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 238000010200 validation analysis Methods 0.000 claims 2
- 108010000239 Aequorin Proteins 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 238000000018 DNA microarray Methods 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 208000010362 Protozoan Infections Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010046555 Urinary retention Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 108010041089 apoaequorin Proteins 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 230000037011 constitutive activity Effects 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 150000001982 diacylglycerols Chemical class 0.000 claims 1
- 230000003292 diminished effect Effects 0.000 claims 1
- 230000035558 fertility Effects 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 238000002493 microarray Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000000159 protein binding assay Methods 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 238000003572 second messenger assay Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000005748 tumor development Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21291300P | 2000-06-20 | 2000-06-20 | |
| US21749400P | 2000-07-11 | 2000-07-11 | |
| EP01870015 | 2001-01-26 | ||
| EP01870024 | 2001-02-12 | ||
| PCT/BE2001/000104 WO2001098330A2 (en) | 2000-06-20 | 2001-06-20 | A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004500125A JP2004500125A (ja) | 2004-01-08 |
| JP2004500125A5 true JP2004500125A5 (https=) | 2005-02-24 |
Family
ID=56290152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002504285A Pending JP2004500125A (ja) | 2000-06-20 | 2001-06-20 | アンギオペプチンによって確認される機能性受容体としてのＧＰＣＲｘ１１を発現し、アゴニストおよびアンタゴニストのスクリーニングに役立つ組換え細胞系 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1297003A2 (https=) |
| JP (1) | JP2004500125A (https=) |
| AU (1) | AU2001265717A1 (https=) |
| CA (1) | CA2413435A1 (https=) |
| WO (1) | WO2001098330A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2367297A (en) * | 2000-07-07 | 2002-04-03 | Smithkline Beecham Corp | AXOR95 polypeptides and polynucleotides |
| AU2001277963A1 (en) * | 2000-07-21 | 2002-02-05 | Millennium Pharmaceuticals, Inc. | 65494, a human g-protein-coupled receptor family member and uses thereof |
| US20030171541A1 (en) * | 2001-02-14 | 2003-09-11 | Amgen Inc., A Corporation Of The State Of Delaware | G-protein coupled receptor molecules and uses thereof |
| DE60228559D1 (de) * | 2001-04-25 | 2008-10-09 | Astellas Pharma Inc | Guanosintriphosphat-bindungsprotein-gekoppelter rezeptor place 6002312 und sein gen sowie dessen produktion und verwendung |
| WO2003027142A1 (fr) * | 2001-09-21 | 2003-04-03 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveau recepteur couple a la proteine g |
| EP1474176A4 (en) * | 2001-11-26 | 2005-06-15 | Bristol Myers Squibb Co | HUMAN G PROTEIN-COUPLED RECEPTOR, HGPRBMY31, VARIANTS AND METHODS OF USING THE SAME |
| EP1340979A3 (en) * | 2002-02-27 | 2004-02-04 | Pfizer Limited | Neuropeptide receptor and uses thereof |
| DE10225443A1 (de) * | 2002-06-08 | 2003-12-18 | Aventis Pharma Gmbh | Verfahren zur Identifizierung von Agonisten oder Antagonisten für den G-Protein gekoppelten Rezeptor mas like 1 |
| AU2003276136A1 (en) * | 2002-11-04 | 2004-06-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1) |
| US7056685B1 (en) | 2002-11-05 | 2006-06-06 | Amgen Inc. | Receptor ligands and methods of modulating receptors |
| US20060240013A1 (en) * | 2002-11-22 | 2006-10-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with bile acid g-protein-coupled receptor 37 (bg37) |
| US7189524B1 (en) | 2002-11-25 | 2007-03-13 | Amgen, Inc. | Receptor ligands and methods of modulating receptors |
| DK1644513T3 (da) * | 2003-06-20 | 2011-10-17 | Discoverx Corp | Assay til detektion af proteinbinding |
| WO2008063321A2 (en) | 2006-10-13 | 2008-05-29 | Janssen Pharmaceutica N.V. | Gpr81-ligand complexes and their preparation and use |
| CN116410335B (zh) * | 2023-04-24 | 2024-08-13 | 徐州医科大学 | 一种多肽tat-mrgprx1c及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9704836D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Pharma Inc | Novel receptor |
| WO2001016159A1 (en) * | 1999-08-27 | 2001-03-08 | Smithkline Beecham Corporation | Gpcr, theant |
| EP1220914A1 (en) * | 1999-09-16 | 2002-07-10 | Solvay Pharmaceuticals B.V. | Human g-protein coupled receptor |
| AU784543B2 (en) * | 1999-11-16 | 2006-04-27 | Pharmacia & Upjohn Company | Novel G protein-coupled receptors |
| CN1310945C (zh) * | 1999-11-17 | 2007-04-18 | 阿瑞那制药公司 | 人g蛋白偶联受体的内源形式和非内源形式 |
| EP1242454A2 (en) * | 1999-12-28 | 2002-09-25 | PHARMACIA & UPJOHN COMPANY | G protein-coupled receptors |
| WO2001048189A1 (fr) * | 1999-12-28 | 2001-07-05 | Helix Research Institute | Nouveaux recepteurs couples a une proteine de liaison au guanosine triphosphate, genes de ces derniers, et production et utilisation de ces derniers |
-
2001
- 2001-06-20 WO PCT/BE2001/000104 patent/WO2001098330A2/en not_active Ceased
- 2001-06-20 JP JP2002504285A patent/JP2004500125A/ja active Pending
- 2001-06-20 CA CA002413435A patent/CA2413435A1/en not_active Abandoned
- 2001-06-20 EP EP01942923A patent/EP1297003A2/en not_active Withdrawn
- 2001-06-20 AU AU2001265717A patent/AU2001265717A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004500125A5 (https=) | ||
| KR20010102507A (ko) | 용도 | |
| JPH10262687A (ja) | 新規ヒト１１ｃｂスプライス変種 | |
| WO2000024890A1 (en) | Novel g protein-coupled receptor proteins, dnas thereof and ligands to the same | |
| JP2000106888A (ja) | 新規ｇ―タンパク質結合レセプタ―（ｈｆｇａｎ７２ｙ） | |
| JP2002515233A (ja) | ヒトＥＤＧ３ｓｂ遺伝子 | |
| JP2004500125A (ja) | アンギオペプチンによって確認される機能性受容体としてのＧＰＣＲｘ１１を発現し、アゴニストおよびアンタゴニストのスクリーニングに役立つ組換え細胞系 | |
| JP2000083669A (ja) | Ｃｘｃｒ４ケモカイン受容体のヒトスプライス変異体ｃｘｃｒ４ｂ | |
| CA2239605A1 (en) | Novel g-protein coupled receptor (h7tba62) | |
| JP2001525178A (ja) | ヒト１１ｃｂスプライス変異体に対するアゴニストおよびアンタゴニストの探索方法 | |
| JP2002505872A (ja) | ７回膜貫通ｇタンパク質共役受容体ｅｃｒ６７３ | |
| US20070117138A1 (en) | Splice variant cannabinoid receptor (cb1b) | |
| JPH1175870A (ja) | 新規なヒトｇ−タンパク質結合レセプター（ｈｃｅｐｔ０９） | |
| AU771950B2 (en) | Compositions corresponding to a calcium transporter and methods of making and using same | |
| JP2002512780A (ja) | 新規７ｔｍ受容体ａｘｏｒ−２のクローニング | |
| JP2002508934A (ja) | Ｔｎｆレセプターに対して相同性を有する、新規な核酸およびポリペプチド | |
| JPH1118788A (ja) | Ｇタンパク質共役受容体 ｈｏｆｎｈ３０ | |
| US20030059856A1 (en) | Methods of screening for agonists and agonists of the interaction between the AXOR8 and AXOR52 receptors and ligands thereof | |
| US7696339B2 (en) | Nucleic acid encoding monkey QRFP | |
| JP2002512016A (ja) | Ｅｄｇファミリー遺伝子、ヒトｈ２１８ | |
| JP2002520041A (ja) | Ｇタンパク質共役受容体ａｘｏｒ１０ | |
| US6441133B1 (en) | Thyrotropin-releasing hormone receptor 2(TRHR-2) | |
| JP2009079033A (ja) | 骨芽細胞分化誘導因子遺伝子及びその利用 | |
| JP2002511388A (ja) | ヒトｇタンパク質共役受容体（ｇｐｒ２５） | |
| JP2002522044A (ja) | ７ｔｍ受容体（ｇｐｒ３１ａ）の分子クローニング |